Lineage Cell Therapeutics Cash Flow Statement (2010-2025) | LCTX

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Cash Flow Statement	Mar2021	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025
Operating Activities
Net Income (Quarter)	-1.45M	-4.96M	-7.83M	-28.01M	-7.09M	-6.78M	-6.12M	-6.32M	-4.40M	-5.20M	-7.16M	-4.71M	-6.56M	-5.77M	-3.00M	-3.25M	-6.03M	-19.33M	-3.42M	-6.16M
Depreciation and Depletion (Quarter)
Share-based Compensation (Quarter)	0.10M	0.92M	1.14M	0.92M	1.11M	1.24M	0.99M	0.96M	1.03M	1.28M	1.27M	1.06M	1.16M	1.27M	1.33M	1.31M	1.22M	1.24M	1.20M	1.10M
Deferred Taxes (Quarter)		-0.17M	-1.00M						-1.80M			0.00M
Gains from Sales and Divestitures (Quarter)	0.02M	0.03M	0.05M	0.06M	0.02M	0.03M	0.03M	0.03M	0.08M	0.08M	0.08M	0.08M	0.07M	0.07M	0.07M	0.07M	0.07M	0.07M	0.07M	0.09M
Gains from Investment Securities (Quarter)	5.19M	16.83M	6.25M	-0.03M	5.30M	10.49M	11.26M	12.17M	0.01M	11.11M	25.44M	0.01M	0.34M	0.50M	16.81M	0.03M	-2.31M	12.74M	35.34M	-1.26M
Asset Writedowns and Impairment (Quarter)																		14.80M
Non-cash Items (Quarter)	8.74M	6.39M	0.22M	9.60M	7.43M	8.03M	8.90M	1.36M	13.00M	9.44M	2.05M	0.00M	9.65M	10.50M	5.49M		7.86M	9.42M	10.15M	6.20M
Cash from Operations (Quarter)	-7.42M	-5.42M	-4.85M	-5.87M	21.90M	-7.06M	-5.48M	-8.30M	-11.24M	-6.27M	-5.04M	-6.02M	-5.78M	-5.18M	-5.79M	-6.35M	-4.89M	-5.54M	-3.62M	-4.88M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles (Quarter)	0.11M	0.03M	0.03M	0.03M	0.03M	0.03M	0.05M	-0.01M	0.03M	0.03M	0.03M	0.03M	0.02M
Amortization of Deferred Charges (Quarter)
Depreciation & Amortization (CF) (Quarter)	0.17M	0.16M	0.17M	0.16M	0.15M	0.15M	0.14M	0.14M	0.14M	0.14M	0.14M	0.14M	0.15M	0.14M	0.14M	0.15M	0.16M	0.17M	0.18M	0.19M
Change in Working Capital
Change in Receivables (Quarter)	0.14M	0.22M	-0.25M	0.75M	-50.32M	0.21M	-0.10M	-0.11M	-0.10M	0.24M	-0.01M	0.30M	-0.67M	0.16M	0.17M	0.23M	-0.42M	0.04M	-0.13M	0.83M
Change in Inventory (Quarter)
Change in Accured Expenses (Quarter)	-1.03M	0.08M	1.31M	21.29M	-18.91M	-0.33M	1.66M	-1.13M	-3.46M	-0.48M	0.48M	1.16M	-0.57M	-0.67M	-0.53M	0.10M	-0.10M	-0.35M	0.27M	2.46M
Other Working Capital Changes (Quarter)	-0.09M	0.05M	1.26M	-1.16M	-4.87M	-4.14M	8.49M	0.07M	-2.12M	-2.96M	-0.96M	-1.61M	-1.22M	0.70M	-0.38M	0.40M	-0.69M	-3.12M	2.74M	1.03M
Investing Activities
Capital Expenditures (Quarter)	0.01M	0.13M	0.05M	0.15M	0.05M	0.10M	0.29M	-0.40M	0.19M	0.26M	0.14M	0.09M	0.04M	0.05M	-0.08M	0.55M	0.10M	0.01M	0.01M	0.40M
Sales of Property, Plant and Equipment (Quarter)
Acquisitions (Quarter)
Divestments (Quarter)
Change in Acquisitions & Divestments (Quarter)									23.33M	24.33M	5.83M	-53.30M		0.02M	3.98M	3.00M	2.00M	-2.00M		2.00M
Cash from Investing Activities (Quarter)	10.07M	-0.12M	-0.07M	-0.15M	-0.05M	-0.10M	-40.91M	-5.10M	15.43M	19.16M	2.12M	9.74M	-0.04M	-8.79M	3.89M	2.63M	1.90M	-0.01M	-0.01M	-15.33M
Financing Activities
Other financing activities (Quarter)	0.54M	0.92M	1.14M	0.92M	1.11M	1.24M	0.99M	0.01M	0.04M	1.28M	1.27M		0.02M				0.01M			0.00M
Cash from Financing Activities (Quarter)	20.96M	11.29M	3.72M	0.95M	0.51M	0.03M	0.96M	0.12M	0.00M	5.63M	0.81M	-0.01M	14.02M	0.10M	-0.00M	21.73M	5.04M	-0.31M	1.83M	20.38M
Additional items
Exchange Rate Effect (Quarter)	-0.08M	0.04M	0.01M	0.01M	-0.04M	-0.12M	-0.63M	-0.08M	-0.10M	-0.09M	-0.34M	0.28M	-0.07M	-0.09M	0.04M	0.03M	-0.07M	0.29M	-0.00M	0.18M
Change in Cash (Quarter)	23.53M	5.80M	-1.19M	-5.05M	22.33M	-7.25M	-46.06M	-13.36M	4.08M	18.43M	-2.45M	3.99M	8.13M	-13.95M	-1.86M	18.05M	1.99M	-5.57M	-1.80M	0.35M
Free Cash Flow (Quarter)	-7.43M	-5.54M	-4.90M	-6.02M	21.86M	-7.16M	-5.77M	-7.90M	-11.43M	-6.52M	-5.18M	-6.11M	-5.82M	-5.23M	-5.71M	-6.90M	-4.98M	-5.55M	-3.63M	-5.28M
Net Cash Flow (Quarter)	23.61M	5.76M	-1.20M	-5.07M	22.37M	-7.13M	-45.43M	-13.28M	4.18M	18.52M	-2.11M	3.71M	8.20M	-13.86M	-1.90M	18.02M	2.06M	-5.86M	-1.79M	0.17M

Research Tools

Lineage Cell Therapeutics Cash Flow Statement (2010-2025) | LCTX

Create an account

Sign In

Reset Password